In the heart of the trading day, U.S. stocks soared with the Nasdaq Composite surging over 150 points on a vibrant Thursday.
Maintaining this upward momentum, the Dow climbed 0.49% to reach 39,319.03. Meanwhile, the NASDAQ experienced a remarkable 1% ascent to 16,4340, with the S&P 500 not far behind, rising by 0.75% to a tally of 5,250.72.
Check This Out: Eyes on Walgreens And 2 Other Stocks with Insider Activity
Leading and Lagging Sectors
Within the market, real estate shares staged a lively 1.1% jump on Thursday, illustrating the diverse movements in different sectors. On the other hand, health care shares only managed a modest 0.01% rise in trading.
Top Headline
ConAgra Brands Inc CAG rejoiced in better-than-expected third-quarter financial performance, reflecting a beacon of positivity in the market.
Reportedly, ConAgra witnessed a 1.7% year-on-year sales dip to $3.03 billion but outshone analyst expectations set at $3.01 billion. The adjusted EPS of 69 cents also sailed past the anticipated 65 cents.
Displaying unwavering confidence, ConAgra reaffirmed its outlook for FY24 Organic net sales, projecting a decline within the 1.0% to 2.0% range as compared to fiscal 2023.
Equities Trading UP
The stock market witnessed a theatrical show as TC Biopharm (Holdings) Plc TCBP skyrocketed by 76% to $2.2850. The surge came on the heels of TCBP signing a non-binding letter of intent for the acquisition of NK Platform Technologies, marking a strategic move in the market.
In another riveting performance, shares of Allurion Technologies Inc. ALUR soared by an impressive 116% to hit $3.73. The surge was fueled by the company announcing the commercial availability of its Virtual Care Suite in the U.S., coupled with an initiation of coverage with a Buy rating and a $5 price target by Chardan Capital.
Adding to the spectacle, Candel Therapeutics, Inc. CADL experienced a notable uptick of 39% to $2.3383 after revealing interim data from the randomized phase 2 clinical trial of CAN-2409 in non-metastatic prostate cancer.
Equities Trading DOWN
In a contrasting performance, eFFECTOR Therapeutics, Inc. EFTR witnessed a stark 76% decline to $3.9778. This dip came hot on the heels of the company announcing topline results from the primary analysis of the randomized Phase 2 KICKSTART trial of tomivosertib combined with pembrolizumab in non-small cell lung cancer.
Market watchers noted a somber mood as shares of Achilles Therapeutics plc ACHL slid downwards by 27% to rest at $0.8706 following the company’s release of fourth-quarter financial results. They shed light on interim Phase I/IIa data on the use of clonal neoantigen reactive T cells from the CHIRON study in advanced unresectable or metastatic non-small cell lung cancer, and the THETIS study in recurrent or metastatic malignant melanoma.
Furthermore, KWESST Micro Systems Inc. KWE witnessed a fall of 17% to $0.9385 after announcing a proposed U.S. public offering, contributing to the market’s dynamic landscape.
Also Check This Out: Feast Your Eyes on the Top 3 Real Estate Stocks Setting Portfolio Alight
Commodities
Turning to commodities, the market witnessed a 0.2% decline in oil trading at $85.27, while gold surged by 0.4% to hit $2,317.30.
On Thursday, silver enjoyed a 0.5% uptick to $27.185, with copper climbing by 1% to $4.2365, setting the stage for a diverse market performance.
Euro zone
Across the pond, European shares witnessed a buoyant trend with the eurozone’s STOXX 600 rising by 0.22%. Notably, London’s FTSE 100, Spain’s IBEX 35 Index, the German DAX, French CAC 40, and Italy’s FTSE MIB Index showcased varying degrees of growth, reflecting a diverse and vibrant market atmosphere.
Notable movements include a 1.0% fall in industrial producer prices in the eurozone from the previous month in February, showcased against a 0.9% decline in the prior month. Services PMI experienced an uplift to 51.5 in March, as compared to 50.2 in the previous month, painting a rich tapestry of market dynamics.
Delving deeper, the HCOB France services PMI exhibited a dip to 48.3 in March, down from 48.4 a month ago. Meanwhile, German services PMI rose to 50.1 in March versus a preliminary reading of 49.8. The S&P Global UK services PMI witnessed a drop to 53.1 in March from 53.8 in the previous month, underscoring the market’s swift and ever-changing tides.
Asia Pacific Markets
Reflecting the global vibrance of the market, Asian markets witnessed a surge with Japan’s Nikkei 225 rising by 0.81% and India’s S&P BSE Sensex following suit with a 0.5% uptick. India’s HSBC services PMI stood at a high of 61.2 in March, vividly capturing the positive sentiments prevailing in the market.
Economics
On the economic frontier, U.S. witnessed an 11,000 rise in jobless claims to 221,000 in March, marking the highest in two months. Additionally, the U.S. trade deficit surged to $68.9 billion in February, vis-a-vis a revised $67.6 billion gap in the previous month.
Now Read This: Get the Lowdown on Levi Strauss, Conagra Brands And 3 Stocks Poised for Thursday’s Market
